EBS Emergent BioSolutions Inc.
8-K Current Report
Filed: March 3, 2026
Health Care
Pharmaceutical PreparationsEmergent BioSolutions Inc. (EBS) 8-K current report filed with SEC EDGAR on March 3, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 5.02: Departure/Election of Directors or Officers
- Item 7.01: Regulation FD Disclosure
AI Filing Analysis8-K
Item 5.02 · Departure/Election of Directors or Officers
- • John D. Fowler, Jr. appointed Class II director effective March 1, 2026; independent under NYSE standards, joining Audit and Finance Committee
- • Initial RSU grant valued at $270,000, vesting in 3 equal annual installments over 3 years
Item 7.01 · Regulation FD Disclosure
- • Press release issued March 3, 2026 announcing appointment of Mr. Fowler, furnished as Exhibit 99.1
- • Reg FD disclosure signals leadership change deemed material enough for broad investor communication
Other Emergent BioSolutions Inc. 8-K Filings
Get deeper insights on Emergent BioSolutions Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.